Trademark: 79355609
Word
SOM BIOTECH
Status
Pending
Status Code
686
Status Date
Tuesday, March 19, 2024
Serial Number
79355609
Mark Type
5000
Filing Date
Wednesday, July 20, 2022
Published for Opposition
Tuesday, March 19, 2024

Trademark Owner History
SOM INNOVATION BIOTECH, S.A. - Owner At Publication

Classifications
5 Pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for treating metabolic disorders; chemical preparations for pharmaceutical purposes for the treatment of diseases of the nervous system, metabolic disorders, malignant tumors, for activating cellular function, for cardiovascular and cerebrovascular diseases, for the treatment of Parkinson's disease, for the prevention of diseases of the respiratory system, for gastro-intestinal disorders, for the treatment of infectious diseases, for movement disorders, for oncologic diseases, for immune system diseases, for skeletal muscular diseases, for hormone disorders, for skin diseases, for ophthalmologic disease, for gynecological diseases, for hematological diseases and for pediatric diseases; pharmaceutical agents affecting metabolism; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for activating cellular function; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations for the treatment of parkinson's disease; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the treatment of rare diseases being hereditary movement disorders such as Huntington disease, Tourette disease, tardive dyskinesia, hereditary muscular dystrophies, hereditary metabolic disorders, hereditary neurological diseases, amyloidosis, rare neurodegenerative diseases, myotonic dystrophy, spinal muscular atrophy, idiopathic pulmonary fibrosis, multiple sclerosis, neurofibromatosis, Acute Flaccid Myelitis, Devic's syndrome, rare cancers, neuropathic pain, ELA and diabetes; pharmaceuticals, for use in the field of treatment of hereditary diseases being Huntington's Disease, Phenylketonuria, Tay Sachs, Duchenne Muscular Dystrophy, Dystrophinopathies, GM2 gangliosidoses, Niemann Pick Disease, hereditary amyloidosis, hereditary Parkinson's Disease, adrenoleukodystrophy, Dravet syndrome, Batten disease, Fragile X syndrome, Friedrich Ataxia, Lennox Gastaut, Gaucher disease, cystic fibrosis, acute myeloid leukemia, sickle cell disease; pharmaceutical preparations for the treatment of gastro-intestinal disorders; pharmaceutical products for the treatment of infectious diseases; pharmaceuticals, for use in treatment of movement disorders; pharmaceutical preparations for use in oncology; pharmaceuticals for the treatment of immune system disease; pharmaceuticals, for use in the treatment of skeletal muscular diseases; pharmaceuticals, for use in the treatment of hormone disorders; pharmaceuticals, for use in the treatment of skin diseases; pharmaceutical preparations for use in ophthalmology; pharmaceuticals, for use in the treatment of gynaecological diseases; pharmaceuticals, for use in the treatment of haematological diseases; pharmaceuticals, for use in the treatment of paediatric diseases; reagents for use in medical genetic testing; clinical medical reagents; drug delivery agents consisting of compounds that modulate delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, drug detoxifying agents; central nervous system stimulants; respiratory stimulants; cardiovascular drugs used in treating congestive heart failure (CHF); preparations for detecting genetic predispositions for medical purposes; cells for medical use; tumor suppressing agents; pharmaceutical preparations for treatment of tumors, namely, tumor antigens; biopharmaceuticals for the treatment of cancer
42 Clinical research in the field of development of drugs discovered through artificial intelligence technology; biological research; chemical technological research in the field of development of drugs discovered through artificial intelligence technology; biomedical research services; research services in the fields of computation chemistry; medical and pharmacological research services in the field of drug discovery and development through artificial intelligence technology; research and development of vaccines and medicines; research and development in the field of microorganisms and cells; stem cell research services; research in the field of artificial intelligence technology; development of pharmaceutical preparations and medicines; implementation of preclinical trials, namely, conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of oncology, neurology, metabolic diseases, respiratory diseases, cardiovascular diseases, ophthalmologic diseases, gastro-intestinal diseases, dermatological diseases, musculoskeletal diseases, gynaecological diseases, paediatric diseases, infectious diseases, movement disorders, hormone disorders, immune system disorders, neurodegenerative diseases; clinical trials, namely, conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of oncology, neurology, metabolic diseases, respiratory diseases, cardiovascular diseases, ophthalmologic diseases, gastro-intestinal diseases, dermatological diseases, musculoskeletal diseases, gynaecological diseases, paediatric diseases, infectious diseases, movement disorders, hormone disorders, immune system disorders, neurodegenerative diseases; providing scientific information about the results of clinical trials for pharmaceutical products; consultancy pertaining to pharmacology; consultancy relating to research in the field of pharmacogenetics; consultancy relating to pharmaceutical research and development; chemistry consultation; providing information on the subject of scientific research in the field of biochemistry and biotechnology; laboratory analysis in the field of chemistry; design and development of medical technology; information technology (IT) consulting services for the pharmaceutical and healthcare industries; design and development of computer software for use with medical technology; design and development in relation to artificial intelligence technology; drug repositioning research; drug combination research
The mark consists of the words "SOM BIOTECH" written in capital stylized letters. The word "SOM" is depicted in red, grey and black and it is represented in bigger letters than the word "BIOTECH", which is located under "SOM" and it is represented in grey in a smaller size.
The color(s) black, grey and red is/are claimed as a feature of the mark.
"BIOTECH"

Trademark Events
Mar 19, 2024
Official Gazette Publication Confirmation E-Mailed
Mar 19, 2024
Published For Opposition
Feb 28, 2024
Notification Of Notice Of Publication E-Mailed
Feb 28, 2024
Official Gazette Publication Confirmation E-Mailed
Feb 14, 2024
Teas Change Of Correspondence Received
Feb 14, 2024
Applicant/Correspondence Changes (Non-Responsive) Entered
Feb 14, 2024
Teas Change Of Owner Address Received
Feb 14, 2024
Approved For Pub - Principal Register
Feb 14, 2024
Examiner's Amendment Entered
Feb 14, 2024
Notification Of Examiners Amendment E-Mailed
Feb 14, 2024
Examiners Amendment E-Mailed
Feb 14, 2024
Examiners Amendment -Written
Feb 2, 2024
Teas/Email Correspondence Entered
Feb 1, 2024
Correspondence Received In Law Office
Feb 1, 2024
Teas Response To Office Action Received
Jan 10, 2024
Teas Change Of Correspondence Received
Jan 10, 2024
Teas Change Of Domestic Representatives Address
Jan 10, 2024
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 10, 2024
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jan 10, 2024
Applicant/Correspondence Changes (Non-Responsive) Entered
Jan 10, 2024
Teas Change Of Owner Address Received
Aug 28, 2023
Refusal Processed By Ib
Aug 5, 2023
Non-Final Action Mailed - Refusal Sent To Ib
Aug 5, 2023
Refusal Processed By Mpu
Jun 30, 2023
Non-Final Action (Ib Refusal) Prepared For Review
Jun 29, 2023
Non-Final Action Written
Jun 26, 2023
Non-Final Action (Ib Refusal) Withdrawn For Review
May 17, 2023
Non-Final Action (Ib Refusal) Prepared For Review
May 16, 2023
Non-Final Action Written
May 5, 2023
Assigned To Examiner
Dec 2, 2022
Application Filing Receipt Mailed
Nov 28, 2022
New Application Office Supplied Data Entered
Nov 25, 2022
Limitation From Original Application Entered
Nov 17, 2022
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24